Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Targeted Therapy and Immune Checkpoint Inhibitors on Prognosis and Surgical Outcomes in Conversion Surgery for Stage IV Gastric Cancer

NCT07009600 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07009600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07009600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Targeted Therapy and Immune Checkpoint Inhibitors on Prognosis and Surgical Outcomes in Conversion Surgery for Stage IV Gastric Cancer
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
January 1, 2010
Completion date
December 31, 2024
Enrollment
124 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iv